Why is Pfizer falling/rising?

As of 04-September, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,150.20, which reflects a decrease of 47.3 points or 0.91%. The stock has underperformed its sector today by 0.76%, and its delivery volume has fallen by 9.56% compared to the 5-day average, indicating a decrease in investor participation. Over the past week, the stock has decreased by 0.83%, while it has shown a modest increase of 2.89% over the past month. However, year-to-date, the stock is down 1.98%, and it has significantly underperformed over the past year with a decline of 16.80%. Despite these challenges, Pfizer maintains a high management efficiency with a return on equity of 18.22% and a low debt-to-equity ratio, which are positive indicators for the company's financial health.
In the broader market context, the Sensex has increased by 0.80% over the past week, contrasting with Pfizer's decline, which suggests that the stock is not keeping pace with the overall market performance. While Pfizer has shown a positive return of 21.13% over the past three years, the recent short-term performance indicates a struggle to attract investor interest, especially given the high dividend yield of 3.2% at the current price. The stock's liquidity remains adequate for trading, but the falling delivery volume may signal a lack of confidence among investors, contributing to the current downward price movement.